Collected data
malignancy, neoplasia, TBLC, bleeding
ADVERSE EVENTS, NEOPLASIA, BLEEDING
Demographic information, lung function tests, nodule attenuation and size, sPAP, duration of procedure, TBB and TBLC pathological results, result of any subsequent surgical or non-surgical biopsy, adverse events, length of hospital stay, and post-operative follow-up were collected. The final diagnosis was determined after a minimum of 12 months of follow up. It allowed to determine the true diagnosis (malignant or nonmalignant). All cases were followed according to the practitioner’s judgment (e.g., surgical tissue biopsy, CT-guided transthoracic needle biopsy, serial CT imaging, and lung health visits). Unconclusive ENB cases with subsequent diagnostic tests confirming a nonmalignant diagnosis or without lesion progression on radiographic follow-up were considered true-negative (TN) for malignancy. Alternatively, if follow-up diagnostic test revealed malignancy or growth of the lesion or if patients underwent a stereotaxic radiotherapy (high probability of neoplasia), unconclusive ENB result was considered as false-negative (FN).Bleeding was assessed using an adapted scoring system previously used by our group for bleeding following TBLC [